ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1425

Current Tobacco Use and the Rates of Complications after Total Hip Arthroplasty

Jasvinder A. Singh, University of Alabama at Birmingham, Birmingham, AL

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Hip, surgery, tobacco use and total joint replacement

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Orthopedics, Low Back Pain and Rehabilitation Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

The risk of postoperative complication with tobacco use disorder and complication after total hip arthroplasty (THA) are not known. Our objective was to compare the rates of complications in current tobacco users and non-users who underwent primary THA.

Methods:

All patients who underwent primary THA at the Mayo Clinic from 2010 to 2013 were included.  Current tobacco use was defined as the use of cigarettes, cigars, pipes or smokeless tobacco reported by the patients at the time of their surgery. We used Cox proportional hazards regression to assess the association of current tobacco use status with each post-THA complication, using hazard ratio (HR) and 95% confidence intervals (CI), and Kaplan-Meier survival to estimate the implant survival. 

Results:

Tobacco use status was available for 3,649 patients (95%) and not available for 197 patients (5%); 3,312 (92%) were current tobacco users.  Among current tobacco users, higher proportion were male (p<0.001), or were 71-80 or ≥80 years old (p=0.02 and p<0.001; reference ≤60); no differences were noted for BMI, cemented vs. uncemented implant, Charlson index or ASA class. 

Compared to current tobacco non-users, the hazards were significantly higher in current tobacco users for deep infection, hazard ratio of 2.89 (95% CI: 1.26,6.64; p=0.01).  Non-significant trends for higher hazards were noted for rates of any infection at 1.66 (0.78,3.49; p=0.19), and any revision, 1.66 (0.82,3.35; p=0.16).  No significant differences were noted for superficial infection and periprosthetic fracture by current tobacco use.

Conclusion:

We noted that current tobacco use was associated with high risk of infection after primary THA.  Future studies should determine the optimal time for tobacco use cessation before elective surgeries such as THA.

 

Endpoint

Variable

# events

1 year (95% CI)

2 years (95% CI)

HR (95% CI)

p-value

Any revision

Current tobacco user

9

94.1 (90.2,98.1)

94.1 (90.2,98.1)

1.66 (0.82,3.35)

0.16

 

Past user or never used

61

97.5 (96.8,98.2)

96.7 (95.8,97.6)

1.0 (ref)

 

 

Revision for aseptic loosening

Current tobacco user

0

100

100

0.56 (0.03,10.95)

0.70

 

 Past user or never used

10

99.5 (99.1,99.8)

99.3 (98.9,99.7)

1.0 (ref)

 

 

Revision for infection

Current tobacco user

3

98.4 (96.5,100)

98.4 (96.5,100)

1.55 (0.46,5.21)

0.48

 

 Past user or never used

21

99.1 (98.7,99.5)

99.0 (98.5,99.4)

1.0 (ref)

 

 

Revision for peri-prosthetic fracture

Current tobacco user

1

99.2 (97.7,100)

99.2 (97.7,100)

1.79 (0.21,15.19)

0.59

 

 Past user or never used

6

99.8 (99.6,100)

99.7 (99.4,100)

1.0 (ref)

 

 

Complication deep infection

Current tobacco user

7

97.1 (94.9,99.2)

97.1 (94.9,99.2)

2.89 (1.26,6.64)

0.01

 

Past user or never used

26

98.9 (98.5,99.4)

98.8 (98.3,99.3)

1.0 (ref)

 

 

Complication superficial infection

Current tobacco user

1

99.6 (98.7,100)

99.6 (98.7,100)

0.41 (0.06,3.03)

0.38

 

Past user or never used

25

98.9 (98.5,99.4)

98.9 (98.5,99.4)

1.0 (ref)

 

 

Complication any  infection

Current tobacco user

8

96.6 (94.3,99.0))

96.6 (94.3,99.0)

1.66 (0.78,3.49)

0.19

 

 Past user or never used

51

97.9 (97.3,98.5)

97.7 (97.1,98.4)

1.0 (ref)

 

 

Complication wound complications

Current tobacco user

5

97.5 (95.3,99.8)

97.5 (95.3,99.8)

1.30 (0.51,3.28)

0.59

 

 Past user or never used

40

98.5 (98.0,99.0)

98.3 (97.7,98.8)

1.0 (ref)

 

 

Complication peri-prosthetic fracture

Current tobacco user

8

97.5 (95.6,99.4)

97.5 (95.6,99.4)

0.78 (0.39,1.59)

0.50

 

Past user or never used

103

96.4 (95.7,97.1)

96.1 (95.4,96.9)

1.0 (ref)

 

 

 


Disclosure: J. A. Singh, Takeda, Savient, 2,Takeda, Savient, merz, Regeneron, Allergan, Crealta, Bioiberica, 5;

To cite this abstract in AMA style:

Singh JA. Current Tobacco Use and the Rates of Complications after Total Hip Arthroplasty [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/current-tobacco-use-and-the-rates-of-complications-after-total-hip-arthroplasty/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/current-tobacco-use-and-the-rates-of-complications-after-total-hip-arthroplasty/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology